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Pharmacokinetics and pharmacodynamics
of sotalol in a pediatric population with
supraventricular and ventricular
tachyarrhythmia
Objective: This pharmacokinetic-pharmacodynamic study was designed to define the steady-state relation-
ship between pharmacologic response and dose or concentration of sotalol in children with cardiac arrhyth-
mias, with an emphasis on neonates and infants.
Methods: The treatment consisted of an upward titration with unit doses of 10, 30, and 70 mg of sotalol
per square meter of body surface area. The patients received 3 doses at each dose level. The dosing inter-
val was 8 hours. The Class III and β-blocking activities of sotalol were derived from the QT and R-R
intervals, respectively, of the surface electrocardiogram, which was recorded at 6 scheduled times before
and after the third, sixth, and ninth doses. During these three dose intervals, 4 scheduled blood samples
were also collected. Drug concentrations were measured with a validated nonstereoselective liquid chro-
matographic tandem mass spectrometric detection assay. Pharmacokinetic and pharmacodynamic parame-
ters were obtained with standard methods.
Results: Twenty-one centers enrolled 25 patients in the study: 7 were neonates, 9 were infants, and 11 were
children between the ages of 2 years and 12 years. The area under the drug concentration-time curve
increased proportionately with dose. The apparent oral clearance of sotalol was linearly correlated with
body surface area and creatinine clearance. The smallest children (body surface area <0.33 m2) displayed
greater drug exposure than the larger children. The increase of QTc and R-R intervals was dose dependent.
At the 70-mg/m2 dose level, the mean (± standard deviation) maximum increase for the QTc interval was
14% ± 7% and the average Class III effect during a dose interval was 7% ± 5%. At the same dose level, the
mean maximum increase of the R-R interval was 25% ± 15% and the average β-blocking effect during a
dose interval was 12% ± 13%. The effects tended to be larger in the smallest children. The Class III response
and the plasma concentrations of sotalol were linearly related. The treatment was well tolerated.
Conclusions: The steady-state pharmacokinetics of sotalol were dose proportionate. Pharmacologically
important β-blocking effects were observed at the 30-mg/m2 and 70-mg/m2 dose levels. Important Class
III effects were seen at the 70-mg/m2 dose level. The Class III effect was linearly related to the drug con-
centration. (Clin Pharmacol Ther 2001;69:145-57.)
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The Class III antiarrhythmic sotalol that elicits Class
III and nonspecific β-blocking activity has been used
in children for indications similar to those in adults.1-6
In adult subjects, the pharmacokinetics of sotalol are
characterized by dose proportionality, renal excretion
of the unchanged drug as the major route of elimina-
tion, lack of metabolism, and negligible plasma protein
binding.7,8
The goal of this prospective, multiple-dose pharma-
cokinetic-pharmacodynamic study was to define the
pharmacokinetics and the relationship between the
pharmacologic effects and dose or drug concentrations
for sotalol in at least 2 of the youngest pediatric age
groups, neonates and infants, with supraventricular
tachyarrhythmia (SVT) or ventricular tachyarrhythmia
(VT). In another single-dose pharmacokinetic study, the
pharmacokinetics were determined in the following 4
age categories: neonates (0-30 days), infants (>1
month-2 years), preschool children (>2-< 7 years), and
school children (7-12 years).9
METHODS
Design and treatment. The treatment consisted of an
upward titration with the use of 3 dose levels with unit
doses of 10, 30, and 70 mg/m2 administered every 8
hours and corresponding to daily doses of 30, 90, and
210 mg/m2. The patients received 3 doses at each dose
level. Depending on tolerability, the dose was titrated
upward every fourth dose.
The 3 dose levels chosen left sufficient spread
between them. The intermediate dose level of 90
mg/m2/d was derived from the initial daily dose of 160
mg defined in the package inserts for adults, with the
assumption of an adult body surface area (BSA) of 1.73
m2.1,6 This dose was expected to generate some mea-
surable β-blocking activity and little Class III activity
in the pediatric population. The highest daily dose level
selected (210 mg/m2) was considered to be the highest
safe dose in children, and pharmacologically signifi-
cant prolongations of the QTc and R-R intervals were
anticipated. Pharmacologically important effects were
not expected after the lowest daily dose of 30 mg/m2.
On consideration of reported break-through arrhyth-
mias in children receiving the adult regimen of every
12 hours and to decrease the fluctuation of the drug
concentrations in the pediatric population, a regimen
of every 8 hours was used.4
Pediatric patients of any sex or race with an age
between birth and 12 years with SVT or VT and who
required therapy were eligible for participation in the
study. Excluded were patients with low body weight (<2.0
kg), patients with advanced congestive heart failure (New
York Heart Association [NYHA] Class III or IV), patients
with significant diseases of organ systems other than the
heart that could interfere with conduct or outcome of the
study, patients with renal impairment (creatinine clear-
ance ≤0.80 of normal value for age), those with hypoten-
sion, those with bradycardia, those with bronchial asthma,
those with acquired or inherited long QT syndrome,
patients with uncorrected hypokalemia, hypomagne-
semia, or hypocalcemia, patients with anemia, patients
undergoing concomitant therapy with β-blocking agents
or antiarrhythmics (excluding digoxin and adenosine) or
drugs prolonging the QT interval, and patients undergo-
ing therapy with oral or intravenous amiodarone for more
than 3 days within the 3 months before the start of the
study. In the event of an arrhythmia occurrence, adeno-
sine could be administered for conversion. External direct
current cardioversion and pacing cardioversion could also
be performed if necessary to convert to sinus rhythm.
The patients were hospitalized during the study. The
doses were normalized for BSA and administered as an
extemporaneously compounded syrup formulation pre-
pared by dissolving the tablets of sotalol. The doses
were given by means of graduated syringes, and the
contents were carefully squirted into the mouths of the
patients. Swallowing of the syrup was supervised. After
the dose of sotalol, the patients received 25 to 50 mL
of a clear liquid of ambient temperature orally. Xan-
thine-containing food and beverages were not permit-
ted from 48 hours before the administration of sotalol
to the end of the study periods. No liquid or solid food
was to be consumed 30 minutes before dosing until 30
minutes after the dose. Fluids were allowed ad libitum.
No strenuous physical activity was permitted during the
study periods.
Safety assessment included monitoring for adverse
events (AEs), for clinical laboratory evaluation, and for
vital signs; a complete physical examination; measure-
ment of the body temperature, blood pressure, and heart
rate; a 12-lead electrocardiogram (ECG); and hematol-
ogy, biochemistry, and urinalysis evaluations. In addi-
tion, the ECG of each patient was monitored telemetri-
cally until at least 8 hours after the last dose. Except for
infants, blood pressure was measured with the patients
in the supine position after the they had rested quietly
for 10 minutes. Blood pressure and heart rate were also
measured just before each dose and 2 hours after dos-
ing. Height and body weight were measured at screen-
ing and just before dosing for computation of BSA.
The study was conducted in accordance with the
principles of the Declaration of Helsinki and subse-
quent amendments. The institutional review boards
of all participating investigational centers reviewed
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and approved the study protocols. The parents or
guardians and the participating child, as appropriate,
gave informed consent.
Procedures. The first dose of sotalol was adminis-
tered to the children at 4:00 PM. Subsequent doses were
given in 8-hour intervals. Blood samples were collected
at 0.5, 2, 4, and 8 hours, and ECGs were recorded at 0.5,
1.5, 2, 3, 4, and 8 hours after the third, sixth, and ninth
doses. Blood samples for pharmacokinetic assessment
were centrifuged at 1000g to 3000g for 15 minutes
within 15 minutes after collection, and the separated
plasma was pipetted into screw-capped polypropylene
microtubes. The plasma samples were kept at –20°C
until analysis.
Surface electrocardiographic tracings and blood sam-
ples were collected at scheduled times. The ECGs were
recorded with the patients resting. Baseline QT and R-R
intervals were determined over a 7.5-hour time interval
between 8:00 AM and 4:00 PM on the first study day.
Analytical method. Plasma concentrations of sotalol
were determined by a validated nonstereoselective liq-
uid chromatographic method with tandem mass spec-
trometric detection.10* In brief, the method used
albuterol as internal standard and a C-18 solid phase
extraction with 2% formic acid in methanol as the elu-
ating solvent. The organic extract was evaporated under
nitrogen to dryness, and the residue was reconstituted
in 10% methanol in HPLC water and then injected into
the liquid chromatography tandem mass spectrometry
system. The drug and the internal standard were sepa-
rated by a reverse-phase liquid chromatography. A
Sciex API 365 or 3000 tandem mass spectrometer
equipped with a heated nebulizer was operated in the
positive ion mode. Multiple reaction monitoring with
the use of the parent→daughter ion combinations of
m/z 273→213 and 240→148 was used to quantify
sotalol and the internal standard, respectively. The
recoveries of sotalol and albuterol (INN, salbutamol)
were approximately 90% and 89%, respectively. The
method was validated in the plasma concentration range
of 1 to 500 ng/mL with adequate assay precision and
accuracy. The interassay variation ranged from 8.1% to
11.5%, and the accuracy ranged from 2.5% to 5.7%.
Appropriate dilution quality-control samples were pre-
pared and run with diluted samples. On the basis of
the extraction of 0.05 mL of plasma, the limit of quan-
tification was set to 1 ng/mL. A typical analytical
run consisted of quality-control standards, calibration
standards, and matrix blanks with internal standard
added.
Data analysis. The pharmacokinetic and pharmaco-
dynamic parameters were obtained in accordance with
standard compartment model independent methods.
Pharmacokinetics. The following pharmacokinetic
parameters of sotalol were determined at each of the
three dose levels: the nominal maximum steady-state
drug concentration measured 2 hours after administra-
tion (C ssmax), the nominal minimum steady-state drug
concentration measured 8 hours after administration,
the area under the drug concentration-time curve
(AUCss), the apparent oral clearance (Cl/F), the aver-
age drug concentration during a dose interval (C ssave),
and the fluctuation factor. The AUCss was computed for
the time interval of 0.5 to 8.0 hours after administra-
tion with the use of the linear trapezoidal rule. Trun-
cated areas measured over time intervals of less than
7.5 hours were also computed when individual plasma
concentration values were missing. The Cl/F was
obtained from the following equation:
Cl/F = D/AUCss
in which D is the dose. Cssave was obtained from the fol-
lowing equation:
Cssave = AUCss/7.5 hours
The fluction factor values were calculated from the
ratio of the C ssmax values to the nominal minimum
steady-state drug concentration values.
Creatinine clearance (CLCR) was computed from the
following equation:
K × height (cm)/serum creatinine concentration (mg/dL)
in which K equals 0.45 for patients who were younger
than 1 year and 0.55 for patients who were 1 year and
older.11 Body surface area was computed from the fol-
lowing equation12:
BSA (m2) = (height(cm)× BW (kg)/3600).12
Pharmacodynamics. The mean QT and R-R inter-
vals were determined from 3 to 5 consecutive sinus
beats at each recording time. The QTc interval was
obtained from the Bazett’s formula13 (QTcB = QT ×
R-R–1/2) or Fridericia’s formula14 (QTcF = QT ×
R-R–1/3), in which QTc and QT are in milliseconds and
R-R is in seconds.
The following pharmacodynamic parameters were
obtained: the respective areas under the QTc or R-R
interval versus time curves at baseline (AUEb) and after
drug administration measured during the third, sixth,
and ninth dose interval at each dose level (AUEss). The
values for AUEb and AUEss were computed over a time
interval of 7.5 hours between 8:30 AM and 4:00 PM.
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*Summary of findings is available on request.
Truncated areas measured over time intervals smaller
than 7.5 hours were also computed when values were
missing. Baseline corrected values were obtained from
the following equations:
∆AUEss = AUEss – AUEb
%∆AUEss = 100 × (AUEss – AUEb)/AUEb
The respective observed maximum effect on the QTc
or R-R interval (E ssmax) and the corresponding time
(tE ssmax) were read off the effect versus time listings.
The nominal minimum effect value was measured 8
hours after drug administration (E ssmin). Baseline cor-
rected values were computed for E ssmax (ie, ∆E ssmax and
%∆E ssmax) and for E ssmin (ie, ∆E ssmin and %∆E ssmin) as
described for AUEss. The average effect on the QTc or
R-R interval during a dose interval was estimated from
the following equation:
Essave = AUEss/7.5 hours
in which E ssave is the average effect. Similarly, the
respective average QTc and R-R interval during a cor-
responding time interval at baseline was computed from
the following equation:
Ebave = AUEb/7.5 hours
in which Ebave is the average QTc or R-R interval dura-
tion at baseline. A value for ∆AUEss of more than 5%
was considered to indicate an important Class III or
β-blocking effect. As in adults, the occurrence of exces-
sive effects of sotalol on the QTc interval was evalu-
ated in the pediatric patients with determination of the
number of individuals with QTcB intervals that
exceeded 525 ms or ∆QTcB that exceeded 60 ms at the
different dose levels.1
All of the ECGs were recorded by the same electro-
cardiograph model with each institution using the same
machine (Schiller Model AT2 PLUS; Schiller AG,
Dietikon, Switzerland). The measurements were taken
after a rest period of 10 minutes with the patients in a
supine position with the use of a chart speed of 50 mm/s
and an amplitude of 10 mm/mV. The electrocardio-
graphic data were blinded on site by placement of a
coded label on each recording; this ensured that all
information, including the date and time obtained, was
covered. The recordings were read by a single techni-
cian and reviewed by a cardiologist to determine suit-
ability for QT and R-R interval measurement. Lead II
was used for all measurements except for the occasional
case when it was necessary to use another lead for tech-
nical reasons. R-R intervals were used for 2 purposes:
to correct the QT interval for changes in the heart rate
and to evaluate sinus node activity. Tracings with irreg-
ular R-R intervals (inter-beat variation ∆R-R >10% in
a single recording) were excluded from the analysis of
both QTc and R-R intervals. For patients with preexci-
tation, measurements were performed with use of the
JT interval, the RT interval, or the earliest notch in the
QRS complex at the discretion of the core laboratory
cardiologist. The RT and JT measurements were then
transformed into QT measurements by addition of the
duration of the non-preexcited QR or QRS complex to
the measured value. For tracings in which the first notch
in the QRS complex was used, no further correction
was made. Tracings that showed marked axis shifts
because of a change in preexcitation pattern were
excluded from QT analysis. Patients with a stable, not
intermittent, intraventricular conduction delay were
used for analysis; the reported QT duration was cor-
rected to reflect normal QRS duration for age rather
than the actual measured QRS complex. Other reasons
for excluding QT interval from the analysis were flat T
wave and motion artifact.
The electrocardiographic tracings were placed on a
digitizing pad (SummaSketch III; Summagraphics,
Seymour, Conn). The end of the T wave was deter-
mined by manual drawing of a tangent to the steepest
portion of the down-sloping T wave. The point at which
the tangent intersected the isoelectric line was used to
designate the end of the T wave.
Plots of QTc or R-R intervals against time were used
to exclude a possible time-dependent variation of the
QTc or R-R intervals during the baseline session. Plots
of the baseline QTcB or QTcF values against the R-R
intervals were used to test the adequacy of the Bazett
or Fridericia formula for correcting the QT intervals for
heart rate.
The impact of congestive heart failure (NYHA Class
I or II) and digoxin coadministration on the pharmaco-
kinetics or pharmacodynamics of sotalol was evaluated
by exploratory methods. Digoxin was the only drug that
was chronically coadministered to 3 patients.
Statistics. Mean values, standard deviations, and
coefficients of variation for the pharmacokinetic and
pharmacodynamic parameters were calculated. Linear
regression analyses were performed for evaluation of
the relationship between Cl/F and BSA or CLCR. The
generalized Estimating Equation Model was used to
explore the relationship between pharmacologic effect
and dose or concentration of sotalol. A normal proba-
bility distribution was used in the model with the use
of the pharmacokinetic parameters as covariates and
the dose or drug concentration level as a class variable.
The multivariate analysis of variance model was used
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to estimate correlation coefficients. The model included
repeated measures with the following factors: patients
and dose level. For comparisons of pharmacologic
effect or pharmacokinetic parameters between patients
with BSAs of more than 0.33 m2 and those with BSAs
of less than 0.33 m2, we used the mixed model with the
dose level as covariate. The sample size of the targeted
neonatal or infant population with SVT or VT was
based on clinical and logistic rather than statistical con-
siderations.
RESULTS
The results are reported as mean values (± standard
deviations) unless stated otherwise. Twenty-one study
sites participated. Twenty-five patients were enrolled
in the study (Table I). The age range of the patients was
7 days to 12.2 years. Thirteen patients were male and
12 were female. Twenty patients were white, 3 were
black, 1 was Hispanic, and 1 was of other ethinic ori-
gin. All of the patients had age-related normal CLCR val-
ues that ranged from 22 to 170 mL/min/1.73 m2.
Twenty-three of the patients had SVT, 1 patient had VT,
and 1 patient had both SVT and VT. Of 9 patients diag-
nosed with Wolff-Parkinson-White syndrome, 7 had
preexcitation. Four patients were diagnosed with mild
congestive heart failure (NYHA Class I or II), which
was attributed to SVT before screening. Left ventricu-
lar dysfunction was diagnosed in utero by echocardiog-
raphy in 1 patient; it resolved at birth. Three patients
received a continuous regimen of digoxin. One of these
patients was also diagnosed with mild congestive heart
failure (NYHA Class I or II). In addition to digoxin, a
variety of drugs were coadministered to some of the
patients during the study.
Pharmacokinetics. Pharmacokinetic data were avail-
able for all 25 patients. However, not all pharmacoki-
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Table I. Demographics of pediatric patients
CLCR
HT BW BSA (mL/min/ Type of Digoxin
Patient No. Age Sex Race (cm) (kg) (m2) 1.73m2) arrhythmia CHF comedication
Neonates 30 d and younger
1 4 Female White 46.0 2.2 0.17 21.7 SVT +
2 11 Male White 50.0 3.2 0.21 37.5 SVT/VT
3 19 Female White 53.5 3.7 0.23 80.3 SVT*
4 21 Male White 54.0 3.6 0.23 81.0 SVT + +
5 27 Male Black 52.5 4.2 0.25 59.1 SVT†
6 28 Female White 55.0 4.3 0.26 41.3 SVT* +
7 30 Female White 51.0 4.0 0.22 38.3 SVT*
Infants between 1 and 24 mo
8 2.3 Male White 59.0 5.0 0.29 132.8 SVT*
9 2.8 Female White 60.0 4.9 0.29 90.0 SVT +
10 3.0 Male Black 65.5 9.0 0.40 98.3 SVT*
11 3.7 Male White 64.0 7.7 0.37 96.0 SVT*
12 5.2 Female White 64.0 5.5 0.31 96.0 SVT
13 13.5 Male Black 81.0 12.0 0.52 91.1 SVT*
14 15.5 Male White 80.0 12.0 0.52 90.0 VT‡
15 16.0 Female White 76.0 9.9 0.44 114.0 SVT +
16 22.3 Male White 87.0 13.0 0.54 97.9 SVT*
Children between 2 and 12 y
17 2.6 Male White 92.5 15.1 0.62 127.2 SVT*
18 5.8 Female Hispanic 106.5 16.4 0.70 83.7 SVT +
19 5.8 Male White 111.6 19.7 0.78 153.5 SVT
20 7.3 Female White 113.0 23.5 0.86 124.3 SVT
21 7.6 Male Other 127.0 31.6 1.06 116.4 SVT†
22 9.7 Male White 138.5 34.6 1.15 127.0 SVT
23 10.7 Female White 154.2 37.1 1.26 169.6 SVT
24 11.8 Female White 138.0 38.0 1.20 126.5 SVT
25 12.2 Female White 164.0 50.2 1.51 112.8 SVT
HT, Height; BW, body weight; CHF, mild congestive heart failure (NYHA Class I or II).
*Wolff-Parkinson-White syndrome.
†Not included in analysis of QT and R-R intervals.
‡Not included in analysis of R-R interval.
netic parameters could be calculated for all 25 patients
at each of the 3 dose levels. The drug concentrations
increased with dose (Fig 1 and Table II). The AUCss
values increased by factors of 3.00 and 6.70 when the
dose was increased by factors of 3.00 and 7.00, respec-
tively. The corresponding increases of the Cssmax values
were 2.98 and 6.65, respectively. The fluctuation fac-
tors obtained at the 10, 30, and 70 mg/m2 dose levels
for the entire population were 2.03 ± 0.52, 2.13 ± 0.80,
and 1.94 ± 0.58, respectively (Table II). Taken together,
these results indicated that the pharmacokinetics of
sotalol in this pediatric population were dose propor-
tionate.
Significant linear relationships existed between Cl/F
and BSA or CLCR (P < .001; Figs 2 and 3). The small-
est children (BSA <0.33 m2) displayed an importantly
larger drug exposure (AUCss and Cssmax) than those with
a BSA larger than 0.33 m2 (Table III), with the BSA-
normalized doses. An examination of the individual
data of the smallest patients did not indicate any devi-
ation from dose-proportionate linear pharmacokinetics
for sotalol.
Pharmacodynamics. QTc and R-R interval data
were analyzable for 23 and 22 patients, respectively.
However, not all of the pharmacodynamic parameters
for the QTc and R-R intervals could be calculated at
each of the 3 dose levels for the 23 and 22 patients,
respectively, with analyzable data. The plot of the
pooled QTcB or QTcF interval against the correspond-
ing R-R intervals at baseline showed that only the cor-
rection procedure according to Bazett resulted in an
independence of the QTc intervals from the heart rate
(Fig 4). Consequently, we will discuss only the results
obtained with the QTcB intervals. There was no evi-
dence for a systematic time dependency of the QTcB
or R-R intervals observed during the baseline session.
The baseline R-R intervals, but not the corresponding
QTcB intervals, were dependent on BSA (Table IV).
The percentage of change in Essmax, Essmin, and AUEss
values for the QTcB and R-R intervals showed a dose-
dependent increase (Table V). The effect of sotalol on
the R-R interval was greater than that on the QTcB
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Fig 1. Linear plot of the mean and standard deviation of sotalol plasma concentration observed at
the 3 dose levels in the 3 age groups: neonates, infants, and children older than 2 to 12 years.
Table II. Pharmacokinetic parameters of sotalol in the
pediatric patients
Dose level (mg/m2)
10 30 70
Cssmax (ng/mL) n 23 22 22
Mean 331 986 2203
SD 101 440 636
CV (%) 30.3 44.6 28.9
Cssmin (ng/mL) n 22 24 24
Mean 186 546 1256
SD 130 432 752
CV (%) 69.9 79.1 59.9
AUCss (h · ng/mL) n 23 24 24
Mean 1973 5918 13228
SD 868 3030 5292
CV (%) 44.0 51.2 40.0
FF n 22 22 22
Mean 2.03 2.13 1.94
SD 0.52 0.80 0.58
CV (%) 25.7 37.4 29.9
SD, Standard deviation; CV, coefficient of variation; C ssmin, nominal trough
sotalol plasma concentration at steady state measured 8 hours postdose in the
third, sixth, or ninth dose interval; FF, fluctuation factor computed as the ratio
of Cssmax to Cssmin.
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Fig 2. Plot of the Cl/F of sotalol against the BSA at dose levels of 10, 30, and 70 mg/m2 of sotalol.
Fig 3. Plot of the Cl/F of sotalol against CLCR at dose levels of 10, 30, and 70 mg/m2 of sotalol.
Table III. Mean pharmacokinetic and pharmacodynamic parameters of sotalol and BSA in small and large children
Dose
AUCss
IFAUCss C
ss
max IFC ssmax
%∆AUEss
BSA (m2) (mg/m2) n h · ng/mL (%) n ng/mL (%) n QTc n R-R
<0.33 10 9 2529 ± 1175 56.5 9 401 ± 111 40.3 6 5 ± 6 8 7 ± 9
30 10 7708 ± 4079 66.1 9 1219 ± 584 43.3 8 6 ± 6 9 11 ± 12
70 10 16,581 ± 6509 53.1 10 2553 ± 615 28.9 6 10 ± 4 9 14 ± 15
≥0.33 10 14 1616 ± 274 14 286 ± 63 14 0 ± 3 12 2 ± 8
30 14 4640 ± 706 13 851 ± 185 13 2 ± 3 11 7 ± 9
70 14 10,833 ± 2324 12 1981 ± 507 13 5 ± 4 11 11 ± 12
P value* .0021 .0021 .0043 .064
IFAUCss, Increase factor of AUCss in small children compared with large children; IFCssmax, increase factor of Cssmax in small children compared with large children;
%∆AUEss, percentage of increase in area under the QTcB or R-R effect time curve at steady-state, represents average percentage of prolongation of QTcB or R-R
interval during a dose interval.
*The P value was calculated from mixed model with the use of dose level as a covariate.
interval. The tE ssmax values occurred between 2.9 and
3.7 hours for the QTcB interval and between 2.2 and
3.3 hours for the R-R interval after the administration
of sotalol at the 3 dose levels tested. The respective per-
centage of change in AUEss values that reflected the
average effect during a dose interval suggested that a
notable and lasting Class III effect was achieved at the
highest dose level of 70 mg/m2. In contrast, a meaning-
ful and durable β-blocking effect was already achieved
at the 30 mg/m2 level for all groups and even at the low-
est dose level of 10 mg/m2 for the smallest children
(BSA <0.33 m2; Table III).
When the effect data on the QTcB interval obtained
at the 3 dose levels were pooled, the respective values
for Essmax and Essmin (or the respective baseline corrected
parameters) were significantly related to the dose lev-
152 Saul et al
CLINICAL PHARMACOLOGY & THERAPEUTICS
MARCH 2001
Fig 4. Scatter plot of the QTcB and QTcF intervals against the R-R intervals at baseline.
Table IV. Mean baseline values of the QTc and R-R
intervals by BSA
BSA (m2)
Parameter <0.33 ≥0.33
Ebave (QTcB; ms) n 8 14
Mean 405 405
SD 17 25
Ebave (R-R; ms) n 9 12
Mean 440 620
SD 47 162
SD, Standard deviation.
Table V. Mean pharmacodynamic parameters of
sotalol in the pediatric patients
Dose level, mg/m2
10 30 70
QTcB %∆Essmax n 21 21 20
Mean 6 9 14
SD 4 4 7
tEssmax n 22 22 21
Mean 3.7 2.9 3.2
SD 2.8 2.2 2.5
%∆Essmin n 20 20 19
Mean 1 2 5
SD 7 5 7
%∆AUEss n 20 21 19
Mean 1 4 7
SD 5 4 5
R-R %∆Essmax n 20 20 20
Mean 18 23 25
SD 12 16 15
tEssmax n 21 21 21
Mean 2.2 3.3 3
SD 2.3 3 2.3
%∆Essmin n 20 20 20
Mean 1 7 9
SD 12 14 15
%∆AUEss n 20 20 20
Mean 4 8 12
SD 8 10 13
%∆Essmax, Percentage of increase of observed maximum QTcB or R-R inter-
val at steady-state; SD, standard deviation; %∆Essmin, percentage of increase of
nominal minimum QTcB or R-R interval at steady-state; %∆AUEss, percent-
age of increase of area under the QTcB or R-R effect time curve at steady-
state, represents average percent prolongation of QTc or R-R interval during a
dose interval.
els (P < .001). For the R-R interval, only the Essmax val-
ues were significantly related to the dose (P = .0205).
There was significant interpatient variation in the Class
III activity, with a few nonresponders among a major-
ity of responders at the 70 mg/m2 dose level.
Pharmacokinetics and pharmacodynamics. When
the effect data on the QTcB interval obtained at the 3
dose levels were pooled, there was a significant relation-
ship between Essave (or the baseline corrected parameters)
and Cssave (P < .001; Fig 5). In contrast to the QTcB inter-
val, no such relationship with the drug concentration was
apparent for the effect on the R-R interval.
Examination of subpopulations. The drug exposure
parameters, AUCss and Cssmax, were significantly greater
in patients with BSAs of less than 0.33 m2 than in the
larger children (Table III). The overall mean increases
in AUCss and Cssmax were 58.6% and 37.5%, respectively,
in the smallest children. In contrast to the smallest chil-
dren, drug exposure among the larger children was sim-
ilar to the applied dose regimen (Fig 6). BSA with CLCR
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Fig 5. Linear plot of the pooled average QTcB interval (E ssave) against the average sotalol plasma
concentration (Cssave) at steady state.
Fig 6. Plot of the dose-normalized AUCss against BSA in the pediatric patients.
was shown to be the most important predictor for Cl/F.
BSA is more discerning than age, and therefore BSA is a
more appropriate criterion for a subpopulation analysis.
In agreement with the pharmacokinetic data, the
pharmacodynamic results also showed larger percent-
age of change in AUEss values for the QTcB and R-R
intervals in the smallest patients (BSA <0.33 m2; Table
III). The QTcB values were significantly greater than
those in the larger children (P = .0043). As a conse-
quence, relevant and durable Class III effects were
apparent in the smallest children already at the 30 and
10 mg/m2 dose levels, respectively. There was also a
larger proportion of the smallest children with ∆QTcB
values of more than 60 ms at all 3 dose levels compared
with the entire pediatric population tested (Table VI).
QTc values of more than 525 ms were observed in only
2 subjects, a small child with a BSA of less than 0.33
m2 and a larger child with a BSA of 0.33 m2 or more.
Interactions with disease and other drugs. There
was no overt indication that mild congestive heart fail-
ure (NYHA Class I or II) had an important impact on
the pharmacokinetics or pharmacodynamics of sotalol.
There also appeared to be no strong evidence for an
important interaction of digoxin with the pharmacoki-
netics or pharmacodynamics of sotalol. It is unlikely
that SVT or VT had an impact on the pharmacokinet-
ics of sotalol. However, it is possible that the tachy-
arrhythmias increased the interpatient variation of the
Class III or β-blocking activities of sotalol.
Safety. No deaths or serious drug-related AEs were
reported. One patient who received the 10 mg/m2 dose
was dropped from the study because of an increased fre-
quency of sinus pauses. The patient had a history of sinus
pauses and surgical correction for congenital heart disease
(Tetralogy of Fallot). Other cardiovascular AEs were seen
at the 30 and 70 mg/m2 dose levels in 7 patients: 3 patients
(2 infants with a BSA <0.33 m2 and 1 child who was 11.8
years old) experienced QTc or QT prolongations, 1 patient
(a 3-week-old neonate) had an abnormal ECG with left
axis deviation, 1 patient (a 5.8-year-old child) had sinus
bradycardia, 1 patient (a 10.7-year-old child) showed an
increased severity of atrial flutter and reported chest pain,
and 1 patient (a 5.8-year-old child) experienced vasodi-
latation. Except for the vasodilatation, the AEs were rated
to be at least possibly related to sotalol.
DISCUSSION
The adjusted dose regimen applied in this study
resulted in fluctuation factors close to 2.0; this is a
desirable feature considering the relatively narrow ther-
apeutic range of sotalol in adults with the target dis-
ease. The dose adjustment based on BSA applied in this
study led to similar AUCss and C ssmax values in all but
the smallest pediatric patients. In the smallest children
(BSA <0.33 m2), an important increase in drug expo-
sure was observed with the use of the empirically
adjusted doses. These results were also in agreement
with the findings obtained in the smallest children in a
single-dose pharmacokinetic study that was conducted
with neonates, infants, preschool children, and school
children.9 In a population pharmacokinetic analysis of
the combined databases from this study and the phar-
macokinetic study,9 BSA was found to be the most
important covariate.15
It is important to note that smaller clearance values
have been reported in neonates for other drugs that,
similar to sotalol, are mainly excreted unchanged by
the kidney in adults.16,17 The values of CLCR normal-
ized for a BSA of 1.73 m2 in the smallest children (65
mL/min/1.73 m2± 35 mL/min/1.73 m2) were clearly
lower than those in the larger children (127
mL/min/1.73 m2 ± 24 mL/min/1.73 m2); this suggests
a reduced excretory function relative to body size in the
smallest children.
Studies of children of different ages have shown that
the ratio of renal to oral total clearance of digoxin,
a drug similar to sotalol that is mainly excreted
unchanged by the kidney, does not significantly change
during the pediatric developmental and body size
changes.16 Therefore it can be assumed that in children,
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Table VI. Proportion (percentage) of pediatric patients with QTcB of ≥525 ms or increase in QTc above baseline
>60 ms* by BSA and dose level
QTcB ≥525 ms ∆QTcB >60 ms
Dose level (mg/m2) All BSA ≤0.33 All BSA ≤0.33
10 0 0 1/21 (4.8%) 1/9 (11.1%)
30 0 0 2/21 (9.5%) 2/9 (22.2%)
70 2/21 (9.5%) 1/9 (11.1%) 10/21 (47.6%) 5/9 (55.5%)
*More than 15% increase.
as in adults, sotalol is mainly eliminated by the kidney.
The observed close dependence of Cl/F on CLCR sup-
ports this assumption (Fig 3).
Congestive heart failure can have an impact on the
pharmacokinetics and pharmacodynamics of drugs.18,19
However, adults in whom alterations of the pharmacoki-
netics of drugs have been reported were generally in
more advanced stages of the disease (NYHA Class II-
IV)20-25 than the patients in this study (NYHA Class I
or II). In this study, no gross deviations of the pharma-
cokinetics and pharmacodynamics of sotalol in the chil-
dren with mild congestive heart failure were observed.
Also, it is unlikely that an important disease-sotalol inter-
action took place. However, a firm conclusion cannot be
drawn on the basis of the limited database available.
In the absence of a control group, the possible impact
of SVT or VT on the pharmacokinetics or pharmaco-
dynamics of sotalol could not be investigated in this
study. Although the type of tachyarrhythmias in this
study probably did not modify the disposition or the
effects of sotalol significantly, it is possible that SVT
or VT contributed to the observed relevant interpatient
variation of the Class III and β-blocking effects of
sotalol.26
In adults, digoxin is eliminated by the same routes,
in the same proportion, and possibly by the same mech-
anisms as sotalol.27 Digoxin is known to reduce the
heart rate and to shorten the QTc interval.28,29 There-
fore digoxin could theoretically interact with sotalol.
However, the results obtained from this study do not
support the notion of an important digoxin-sotalol inter-
action. Clearly, the database is too limited for a defini-
tive conclusion.
In the entire pediatric population studied, a notable
and lasting β-blocking effect was found, starting at the
30 mg/m2 dose level, whereas a corresponding Class
III effect was only observed at the highest dose level of
70 mg/m2. However, consistent with the increased
plasma concentration, the smallest children (BSA <0.33
m2) had pharmacologically important β-blocking
effects at even the lowest dose level of 10 mg/m2. These
findings were in accordance with reports of adult sub-
jects and patients that have indicated that sotalol elicits
a β-blocking effect at lower doses than the Class III
effect.30,31 It should be noted that in the previous
reports of adults the β-blocking effect on the R-R inter-
val or heart rate was not measured at rest but was mea-
sured after induction of tachycardia by either isopro-
terenol infusion or exercise.30,31
Compared with the pharmacokinetic results, the
dependency of the Class III and β-blocking effects on
the BSA was less certain. The observed increase in drug
exposure, the tendency for more pronounced effects in
the smallest children (BSA <0.33 m2), and the impor-
tant interpatient variation observed in the entire pedi-
atric population mandate sotalol dose regimens that are
guided by QTc interval and heart rate monitoring.
The observed statistically significant relationships
between response and drug concentration for the QTcB
interval in the pediatric population were in accordance
with similar findings in adult subjects.30-34 The absence
of a definable relationship between response and drug
concentration for the R-R interval in the pediatric pop-
ulation may have to do with the possible impact of age
or BSA on this relationship. Also, the R-R intervals
were measured during resting conditions in the chil-
dren, whereas the existence of a relationship between
drug concentration and β-blocking effect of sotalol in
adults was found with the use of exercise- or isopro-
terenol-induced tachycardia conditions.30,31
CONCLUSIONS
The main findings in the 4 pediatric age groups
(neonates, infants, children older than 2 years to 7 years,
and children older than 7 years to 12 years) receiving
multiple doses of 10, 30, and 70 mg/m2 of sotalol with
the use of an extemporaneous formulation were as fol-
lows. (1) The applied dosage regimen with 8-hour inter-
vals for sotalol achieved ideally small fluctuation factor
values of ≈ 2.0 between nominal peak and trough steady-
state concentrations. (2) The pharmacokinetics of sotalol
in the pediatric population were first order and dose pro-
portionate. (3) There were statistically significant corre-
lations between Cl/F and BSA or CLCR. (4) The AUCss
and C ssmax values were similar in patients with BSA
of more than 0.33 m2, but in children with smaller BSA
values, a significantly greater exposure to the drug was
observed with the BSA-normalized dosages.
Notable and lasting Class III effects of sotalol were
observed in the pediatric population at the highest dose
level of 70 mg/m2. Important and durable β-blocking
effects were found at the 30 and 70 mg/m2 dose levels.
Both effects showed important intersubject variation,
which indicated important differences in the respon-
siveness of the individual pediatric patients. The Class
III and β-blocking effects tended to be more pro-
nounced in the smallest children (BSA <0.33 m2). Sta-
tistically significant dose level dependencies existed for
the Class III and β-blocking effects of sotalol in the
pediatric population. Finally, there were statistically
significant linear correlations between drug concentra-
tion and pharmacologic activity on the QTcB interval.
No such correlation could be shown for the β-blocking
effect measured at rest in the children.
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